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on medical conditions by enhancing patient expectancies.
Recent reviews suggest that placebo benefits are restricted to
subjective responses, like pain, but might be ineffective for
objective physiologic outcomes. Nevertheless, mind-body links
and placebo responsivity in asthma are widely believed to exist.
Objective: We carried out a randomized, double-blind
investigation to (1) determine whether placebo can suppress
airway hyperreactivity in asthmatic subjects, (2) quantify the
placebo effect, (3) identify predictors of the placebo response,
and (4) determine whether physician interventions modify the
placebo response.
Methods: In a double-blind, crossover design investigation,
55 subjects with mild intermittent and persistent asthma with
stable airway hyperreactivity were randomized to placebo or
salmeterol before serial methacholine challenges. Subjects were
additionally randomized to physician interactions that
communicated either positive or neutral expectancies
regarding drug effect.
Results: Placebo bronchodilator administration significantly
reduced bronchial hyperreactivity compared with baseline (the
calculated concentration of methacholine required to induce a
20% decrease in FEV1 nearly doubled); 18% of subjects were
placebo responders by using conservative definitions.
Experimental manipulation of physician behavior altered
perceptions of the physician but not the magnitude or
frequency of the placebo response.
Conclusions: Objective placebo effects exist in asthma. These
responses are of significant magnitude and likely to be
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by alterations in physician behavior in this study.
Clinical implications: The placebo response in patients with
asthma is important in understanding the limitations of clinical
research studies and in maximizing safe and effective therapies.
This article confirms the existence of a strong placebo response
in an objective and clinically relevant measure of disease
activity. (J Allergy Clin Immunol 2007;119:1375-81.)
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Recently, there has been a reawakening of interest in
the placebo response. The term placebo, Latin for ‘‘I shall
please,’’ was coined in the early 19 th century to describe
a medicine ‘‘adapted more to please than benefit the pa-
tient.’’1 Current ethical standards forbid the deceptive
use of placebo to treat patients, but placebos are now often
mandatory as controls in clinical studies of new therapeu-
tics. In both cases, the placebos are assumed to have no
significant effect on health. However, across a large num-
ber of clinical trials, benefit is often demonstrated in the
placebo arm, raising the question of whether placebos
can have psychologic, physiologic, and/or health effects.
A definitive health benefit from placebos cannot be
inferred from clinical trials when the natural variation
in the disease outcome is not measured because of the
inability to differentiate between placebo effects and
normal variability in disease status. A meta-analysis of
placebo responses in clinical studies that did contain a
natural history arm found that placebo administration
induced beneficial changes in subjectively assessed out-
comes, such as pain and depression, but not in objectively
defined medical outcomes.2 Although this report has been
widely debated, it clearly questions the notion that place-
bos can affect peripheral physiologic processes or disease
manifestations.
A primary aim of the current study was to determine
whether there is a placebo response in objective measures
of lung function in the context of asthma and, if so, to
estimate the magnitude of that effect relative to natural
variation in lung function and response to active drug.
Asthma is a good disease model in which to study the
placebo effect because disease-relevant objective end
points can be assessed, such as air flow and bronchial
hyperresponsiveness. Also, there is a long history of belief
that psychologic factors play a role in the course of
asthma, which is supported by recent research.3-6 In the
current study we compared the protective effect of the1375
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BMI: Body mass index
PC20: Calculated concentration of methacholine required
to induce a 20% decrease in FEV1
PD20: Dose level of methacholine during which a 20%
decrease in FEV1 was noted
long-acting bronchodilator salmeterol with placebo (the
identical dry powder inhaler emptied of medication) when
administered before a methacholine challenge.
A second aim was to determine the cognitive and
affective mediators of the placebo effect. We hypothesized
that treatment outcome expectancies—beliefs about a
treatment’s efficacy—would mediate placebo effects on
airway hyperresponsiveness.7-9 Expectancies regarding
treatment outcome and disease course have predicted a
variety of health outcomes, although most often in the
setting of subjectively assessed measures.10-15
A third aim of the study was to determine whether the
placebo response can be enhanced by induction of positive
expectancies by a physician before placebo administra-
tion. Physician behavior was scripted to enhance (or not)
positive treatment outcome expectancies and emotional
care, the provision of support, empathy, reassurance, and
warmth.16 A review of studies that manipulated one or
both of these dimensions of physician behavior demon-
strates that positive health outcomes can result from these
behavior patterns.16
METHODS
Participants
Subjects were recruited at the National Jewish Medical and
Research Center and the University of Iowa. Eligible subjects were
men and women, aged 18 to 55 years, with mild intermittent or
persistent asthma17 and a baseline FEV1 of 80% of predicted value or
greater. Major exclusion criteria included pregnancy or breast-feed-
ing, serious systemic illness, recent respiratory tract infection, use
of inhaled corticosteroids or other controller medications within 4
weeks, and smoking (>5 pack-year lifetime history). All subjects pro-
vided written informed consent before screening that did not reveal
that the central purpose of the study was to explore the placebo re-
sponse; this deception was revealed at a debriefing at the end of the
protocol, when subjects were reconsented and given the opportunity
to withdraw from the study. This study was reviewed and approved
by the Institutional Review Boards of the University of Iowa; the
University of California, San Francisco; the University of Missouri,
Kansas City; and the University of Pennsylvania.
Procedures
Trial design. The study used a randomized, placebo-controlled
trial design that included a crossover and required 6 visits (Fig 1). The
first 3 visits (approximately 1 week apart) were used for screening and
to establish the subjects’ baseline characteristics, including the degree
of airway hyperresponsiveness in the untreated state and after pre-
treatment with salmeterol (50 mg, Serevent Diskus, GSK, Research
Triangle Park, NC). At visit 1, they were required to have a calculated
concentration of methacholine required to induce a 20% decrease in
FEV1 (methacholine PC20) of 4.0 mg/mL or less, with a second
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tial value. At visit 3, they needed to demonstrate significant protection
(at least 1 dose level of improvement in PC20) after inhalation of
salmeterol (50 mg, Serevent Diskus, administered in a single-blind
manner). The second phase of the study (visits 4 and 5) included a
double-blind randomized intervention before methacholine chal-
lenge: administration of either placebo (Serevent Diskus from which
the blister tape containing salmeterol was removed) or salmeterol,
with a crossover to the alternate treatment arm. For these visits, the
subjects were also randomized to receive enhanced or efficient inter-
actions with a physician investigator (described below) before the ad-
ministration of the active/sham inhaler: thus 4 groups were constituted
by treatment order (placebo/salmeterol and salmeterol/placebo) and
physician interaction (enhanced vs efficient). Finally, visit 6 consisted
of a debriefing interview, at which time research subjects were in-
formed that the central purpose of the study was to study placebo
rather than treatment response and were provided the opportunity to
withdraw their data from analysis with no penalty (not requested by
any participant). Psychologic assessment included multiple question-
naires throughout the study (see below) that were administered with
the goal of predicting placebo responsiveness. Other factors used in
this analysis included sex, age, weight, and body mass index (BMI).
Pulmonary function measurement. Methacholine challenge test-
ing was carried out according to standard procedures18 to measure air-
way hyperresponsiveness, with serial doubling doses (diluent, 0.16,
0.31, 0.63, 1.25, 2.5, 5, 10, and 25 mg/mL) of methacholine aerosols
with a calibrated dosimeter. The testing technician was blind to con-
ditions. Each subject’s screening methacholine PC20 (an average of
the PC20 measured at visits 1 and 2) served as the baseline for com-
parison with subsequent challenges. The methacholine challenges
during visits 4 and 5 were carried out 1 hour after the subject’s use
of the active/sham inhaler.
Physician encounters. On the basis of the literature, we proposed
that a positive treatment outcome expectation communicated by the
physician at the time of bronchodilator administration would increase
positive expectancies regarding the treatment efficacy and thus
enhance (or in the case of placebo induce) its physiologic effects.
The enhanced physician encounter was designed to emphasize posi-
tive expectations, as well as the authority and supportiveness of the
physician, whereas the efficient encounters minimized these factors,
although they did not convey negative expectations. Enhanced and
efficient physician investigators were selected by each site’s principal
investigator; all had expertise in asthma and possessed an inter-
personal style matching either the enhanced or efficient style. Physi-
cians who conducted the enhanced encounters were trained to
transmit a positive expectation about the bronchodilator efficacy
(for both of the crossover conditions) in reducing methacholine-
induced symptoms by using specific scripted sentences (eg, ‘‘You
shouldn’t have any symptoms’’). Enhanced physician encounters
also promoted authority (physicians wore a white coat and tie, were
introduced as asthma experts, and were trained to speak with author-
ity and conviction) in a supportive environment (encounters were
longer, approximately 10 minutes, and included empathetic and
respectful behavior, such as shaking hands with the subject). Physi-
cians assigned to the efficient encounters were trained to convey an
equivocal expectation about the bronchodilator efficacy (‘‘It might
work, and then again it might not’’) and to minimize authority (no
white coat or tie; introduction as a junior member of the team) and
supportiveness (eg, encounters were about 2 minutes, and physicians
displayed more efficient and brusque, although not negative, behav-
iors, such as inconsistent eye contact). The physician encounters took
place just before administration of the salmeterol or placebo during
visits 4 and 5. For the enhanced encounters, there was an additional
brief interaction between the physician and patient immediately before
the methacholine challenge. Training took place on site by an expert in
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Kemeny et al 1377FIG 1. Trial design. As described in the Methods section, eligibility was determined at 3 screening visits, after
which subjects were randomized to enhanced or efficient physician interactions and to order of premethacho-
line challenge treatment (with a crossover between salmeterol and placebo), followed by a final visit for recon-
senting the subjects. D.B., Double blind; MeChol, methacholine challenge.
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change. Each physician was trained in an individual half-day session.
During the trial, encounters were audio taped and reviewed by the
trainer for maintenance and reinforcement of appropriate behaviors.
Psychologic assessment. Psychologic instruments were included
in an effort to predict the placebo response and to serve as a
manipulation check for the physician encounters. Assessment took
place at the screening visits, as well as before and after the physician
encounters, and focused on mood state (including depression,
hostility, and anxiety), as well as appraisals of current and future
health, treatment, and the physician. The following instruments were
used: the Positive Affect Negative Affect Schedule, the Beck
Depression Inventory, the Spielberger State Anxiety Scale, the
Affect Balance Scale, the Cooke-Medley Hostility Scale, the Life
Orientation Test, the Marlowe-Crown Social Desirability Test, and
the Health Locus of Control scale. The Asthma Stroop Task19 was ad-
ministered as a measure of asthma-specific cognitive interference and
attentional biases. All standardized questionnaires used have good
psychometric properties.
Statistical analyses
Between-group comparisons (enhanced vs efficient condition
effects; placebo responders vs nonresponders) with PC20 and psycho-
logic variables as dependent variables were conducted with t tests and
confirmed with nonparametric Wilcoxon rank sum tests. Paired t tests
were used for within-subject comparisons (eg, PC20 at the placebo
vs screening visits). Mixed-model ANOVAs were also performed
with PC20 values as the dependent variable, including between-sub-
jects factors (enhanced vs efficient condition), within-subject factors
(placebo visit vs salmeterol visit), and their interaction, as well as
covariates.
RESULTS
Participants
Fifty-five subjects completed the study at 2 sites. Five
subjects dropped out after the second screening visit; nonewere disqualified because of unstable airway hyperres-
ponsiveness. The mean age of participants was 29.7 years
(SD, 11.3); women comprised 56.4% of the population,
and 91% of the sample was white. Mean BMI was 30.2
(SD, 6.5). There were no significant differences between
those assigned to the enhanced and the efficient physician
conditions in any demographic, psychologic, or medical
variable assessed during the 3 screening visits, including
baseline spirometry.
Existence of a placebo response
The first question to be addressed was whether a
placebo response exists in airway hyperreactivity. We
found that PC20 was significantly greater after adminis-
tration of placebo than at baseline (the average of the
untreated PC20 at visits 1 and 2; P 5 .001, Fig 2). We
found no effect of treatment order (ie, no difference in
degree of placebo response whether placebo was admin-
istered at visit 4 or visit 5). The response to salmeterol
was significantly greater than that to placebo (P  .001),
with placebo-induced improvement a median of 29% of
the improvement in PC20 attributable to salmeterol.
There was no significant difference between the metha-
choline PC20 after single-blind salmeterol (visit 3) and
double-blind salmeterol (visit 4 or 5). Thus our study
found an objectively measured placebo response in bron-
chial hyperresponsiveness that provided approximately
one third the benefit of active drug (salmeterol) in the
same individuals under identical conditions.
The second aim of this study was to define a placebo
responder to identify determinants or predictors of placebo
response. The study protocol allowed for examination
of the normal variation in airway hyperresponsiveness to
ensure that any placebo response fell outside that range. At
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1378 Kemeny et alFIG 2. Bronchoprovocation response by visit. All subjects demonstrated bronchial hyperresponsiveness (PC20
4 mg/mL) at baseline (average of visits 1 and 2), which was significantly reduced by pretreatment with (sin-
gle-blind) salmeterol at visit 3. Visits 4 and 5 included pretreatment with (double-blind [DB]) placebo or salme-
terol (in a randomized order) before methacholine challenge. Double-blind placebo induced a significant
increase in methacholine PC20 (P 5 .001) compared with baseline values. V, Visit.
FIG 3. Bronchoprovocation response by physician interaction. Subjects were randomized to physician
interaction style (enhanced or efficient for visits 4 and 5) and to premethacholine treatment order (placebo/
salmeterol or salmeterol/placebo). No primary effect of physician interaction style was detected. V, Visit.
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concentrations of methacholine, which induces a decrease
in FEV1 of at least 20% from the baseline value (metha-
choline PD20), which is distinguished from the PC20, an
interpolated value, and the remaining 25.5% had a PD20
within 1 doubling dose of their initial value at the second
screen; no subjects had a difference in PD20 of 2 or more
dose levels. We concluded that a difference of 2 or more
dose levels between the screening and placebo visits was
unlikely because of random variation and post facto de-
fined as placebo responders all subjects who met this cri-
terion. Ten (18.2%) subjects showed a 2-dose difference
between their last screening visit and their placebo visit
(51% showed 1 dose level of improvement). This subsam-
ple had a large placebo/salmeterol PC20 ratio (median,
0.50; mean, 0.86). Unexpectedly, 5 (9%) subjects had a
postplacebo PD20 of greater than 25 mg/mL (the highest
concentration of methacholine used for this study).
Predictors of placebo response
Demographics and psychologic characteristics. Sex
and BMI did not differ between placebo responders versusnonresponders, but responders were significantly younger
than nonresponders (responders, 24.0; nonresponders,
30.9; P  .01). Responders did not differ from nonre-
sponders in baseline psychologic characteristics, includ-
ing positive or negative trait affect, depression, hostility,
or trait optimism (all P > .10).
PC20 responses by physician condition (enhanced vs
efficient). There was no significant difference in the
number of placebo responders in the efficient versus the
enhanced physician conditions (P > .10). In addition,
there was no significant difference between enhanced
and efficient conditions in PC20 levels at either the placebo
or the salmeterol visit (P > .1, Fig 3) nor in the size of the
placebo response (the difference between PC20 at the
placebo and the mean screening visits [mean difference:
enhanced, 2.06; efficient, 2.27; P > .1]). The ratio of
placebo to salmeterol PC20 did not differ by condition
(P> .1). There was not a significant main effect of physician
condition for PC20 in the placebo condition controlling for
values during the screening and single-blind salmeterol
visits (P > .1) or in PC20 levels at the salmeterol visit
(P > .1).
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subjects assigned to the 2 physician encounter groups
differed in their ratings of the physicians, with those
assigned to the enhanced group rating their physicians as
significantly more supportive and optimistic than those
assigned to the efficient group (P < .05), suggesting that
the manipulation of physician behavior successfully al-
tered perceptions in the desired direction. However, the
2 groups did not differ in their treatment outcome expec-
tancies or in their levels of anxiety, positive or negative
mood, or asthma-related cognitive disturbance during
the waiting period (all P > .1), leading us to conclude
that this altered perception did not affect potential media-
tors of the placebo response. Interestingly, across physi-
cian encounter conditions, placebo responders described
their physicians as less optimistic during the encounter
than nonresponders (P < .05), particularly those in the
enhanced condition (P < .05). Responders and nonre-
sponders did not differ in their treatment outcome
expectancies or in the levels of anxiety, positive or nega-
tive mood, asthma-related cognitive disturbance, and
other perceptions of the physician during the period
between the physician encounter and the methacholine
challenge (all P > .1).
DISCUSSION
The last decade has seen an increased interest in the
placebo response in physical disease, and placebo effects
have been documented in numerous conditions.2 Re-
cently, the neural circuitry underlying these effects has be-
gun to be mapped.20 However, the vast majority of studies
examine effects in subjectively experienced outcomes,
such as pain and depression, suggesting higher-order brain
modulation of central processes relevant to these con-
ditions. Relatively little is known about the ability of a
placebo to alter objectively assessed peripheral end points
directly relevant to disease. In this study we demonstrate
that a placebo bronchodilator can significantly reduce
nonspecific airway hyperresponsiveness in asthmatic sub-
jects: postplacebo PC20 was almost twice that observed
during the 2 screening visits. Thus although placebo med-
ications are pharmacologically inert, they can be biologi-
cally active, modulating peripheral physiologic processes,
presumably by activating specific neural circuits.
Using our within-subject design, we defined placebo
responders post facto by comparing airway responses
after administration of placebo bronchodilators with the
subjects’ own untreated baseline responses. We strictly
defined a placebo response as a change greater than any
that occurred between the 2 initial screening visits.
Eighteen percent of subjects were characterized as placebo
responders by using the strict criteria of a 2-dose or greater
difference between screening and postplacebo PD20. In
this highly responsive group the median placebo/salme-
terol PC20 ratio was 50% (compared with 29% overall).
We almost certainly underestimated the number of pla-
cebo responders by using these criteria; 53% of subjectsshowed a 1-dose difference in PD20 between screening
and placebo visits, some of whom were likely manifesting
a placebo response (albeit to a lower degree). We also
found a small group (n 5 5 [9%]) who demonstrated a
less than 20% FEV1 decrease from the maximum metha-
choline concentration, suggesting that in selected indi-
viduals the placebo response can completely eliminate
bronchial hyperreactivity. The potential clinical signifi-
cance of this magnitude of placebo response, much higher
than could be accounted for by natural history or random
variation in responsivity, is substantial. These findings
demonstrate an objectively measured and clinically rele-
vant placebo effect in a cardinal manifestation of a highly
prevalent and morbid disease.
The size of the placebo effect in a clinical trial is often
calculated as the benefit in the placebo arm relative to the
benefit in the active drug arm. In many studies the placebo
effect is about one third of the active drug effect, despite all
the sources of variation that contribute to this value, such
as between-subject differences and random fluctuation.21
Interestingly, we found that the median placebo PC20
over the active drug PC20 was 29%, even in the context
in which between-subject effects were eliminated and
the placebo effect was determined relative to the subjects’
own baseline PC20 values. Thus placebo responses in this
objective outcome might be meaningful clinically.
Although there was substantial variation in the magni-
tude of the placebo response, we were generally unsuc-
cessful in predicting this variability. Many of the factors
(traits such as optimism and negative affect) considered
potential predictors of the placebo response were not
predictive in this context. However, although placebo
responders did not differ from nonresponders on the basis
of sex or BMI, responders were significantly younger, a
finding that merits further study.
We attempted to enhance the placebo response by
physician encounters that promoted positive expectancies
about the efficacy of the prechallenge treatments. Physi-
cians in the enhanced encounters were intensively trained
to convey positive expectancies, communicate authorita-
tively, and engage the research subject supportively.
Subjects assigned to this condition rated their physicians
as significantly more supportive and optimistic than those
assigned to the neutral expectation condition, as was the
goal, suggesting that the physician training was success-
ful. However, manipulating the subjects’ perceptions in
this manner altered neither expectations regarding drug
efficacy nor differences in airway responsivity. Future
research directed at discovering methods for promoting
the placebo response is clearly warranted. We might have
had different results if the physician interactions were
designed to promote enhanced versus negative (rather
than neutral) expectancies; likewise, it is possible that the
adverse symptomatic responses to the methacholine chal-
lenges were too mild to be substantially affected by the
asthmatic subjects’ anticipatory anxiety or expectations.
Self-reported expectations of symptoms before the
methacholine challenge did not predict lung function in
the placebo or active drug conditions. Other psychologic
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specific cognitive disturbance, also did not predict placebo
responses.
Interestingly, subjects’ perceptions of physician opti-
mism appeared to predict placebo response in a direction
opposite to our hypothesis. We found that placebo
responders described their physician as less optimistic
overall. This was true in both groups but most strongly in
the enhanced encounters, despite the physicians’ training
to convey optimism about drug efficacy and overall
(responders plus nonresponders) perception of these phy-
sicians as more optimistic. Placebo responders in the
enhanced condition viewed the physician as moderately
to very optimistic, whereas nonresponders viewed them
as very to extremely optimistic. The relationship between
placebo response and optimistic attributions was not
observed in subjects assigned to the efficient encounter,
with more equivocal expectations. It is possible that
placebo responders have a more accurate or realistic
view of their physicians’ actual drug efficacy expectations
because physicians in the enhanced condition communi-
cated a more optimistic expectation than they knew was
realistic (because all subjects received placebo). This
difference would not be seen in the efficient condition
because those physicians transmitted an equivocal expec-
tation more consistent with their actual view. This finding
is consistent with the trend in the data suggesting that
in the enhanced (but not efficient) condition placebo
responders expected more symptoms with challenge than
nonresponders. Future research might manipulate phy-
sician expectations to determine whether these ‘‘real’’
expectations affect patient placebo responses.
Another possible interpretation of these findings is that
the positive expectation message in the enhanced condi-
tion was muted by the physicians’ enhanced emotional
care/supportiveness behavior (eg, by discussing concerns
more and asking more questions), which could have
inadvertently conveyed that they were not actually opti-
mistic about the subjects’ outcome. With this design, it
was impossible to untangle the effects of the expectancy
part of the manipulation from the supportive care
component.
A great deal is now known about the specific brain
circuits that mediate cognitive control and mood regula-
tion.22-24 Placebo effects on brain activity have been dem-
onstrated in pain, depression, and Parkinson disease.20,25-29
Placebo response appears to involve both cortical re-
gions of the brain involved in cognition and the subcortical
regions that process emotions (including the ventral stria-
tum). Tight linkages have been demonstrated between cor-
tical areas activated by executive functions or affective
states and the deep structures of the brain associated
with peripheral physiologic monitoring and control. We
hypothesize that a placebo response can be mediated
through modulation of neural efferent pathways (inhibition
of cholinergic30 or activation of nonadrenergic-noncho-
linerigic parasympathetic31-34 outflow) or even through
regulation of central nervous system active inflammatory
mediators, such as TNF-a or arachidonic acid
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a greater effect on larger airways,36 nonadrenergic non-
cholinergic innervation responses or modulation of in-
flammatory mediators might be a more likely
mechanism for our findings. Our current findings suggest-
ing placebo control of lung function support the conclu-
sion that the central nervous system correlates of higher
mental function not only affect responses within the brain
itself but might also produce peripheral changes in ways
that can affect health.
We have documented a placebo response in objective,
health-relevant measures of lung function; this contradicts
recent suggestions in the literature that placebo responses
are confined to subjective outcomes, such as pain. Defin-
ing the links between psychologic processes, their neural
substrates, and peripheral physiology is a critically im-
portant area of medicine. According to the Institute
of Medicine, ‘‘since approximately half of all causes of
morbidity and mortality in the United States are linked to
behavioral and social factors it is crucial to improve our
understanding of these issues.’’37 Understanding the na-
ture of the placebo response in disease is one reasonable
approach to addressing these issues.
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